Skip to main content

Table 5 Protocol features in Hollow fiber reactors

From: Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy

Author - Year Pre stimulaiton Cell culture IC Starting material Culture system
Medium Stimulation Serum and supplements Source Inoculation [cells/reactor] Volume [mL] Reactor Fibers Cut off [kDa] Surface area [cm2] Perfusion flow [mL/min] Control
T cells
 Lamers [124] - 1994 IL2, PHA or CD3 mAb AIMV IL2 10% AB Glutamine and glucose + RPMI PBMC 109 NP Immuno*star 4000 10,000 10 NP 50 Control glucose at 1.5 g/L
 Lamers [125] - 1999 IL2, PHA AIMV IL2 NP Glutamine and glucose + RPMI PBMC 1.7–3.1 × 108 100 Immuno*star 4000 10,000 10 NP 50 Control glucose at 2 g/l; control lactate levels
 Liu [126] - 1999 Anti CD3/CD8 mAb CCM IL2 1% AB Medium CD4+ and CD8+ from PBMC 2–8 × 107 NP Cellco Cellmax NP NP NP NP Control glucose at 50–100 mg/dL
 Trickett [127] - 2002 IL2, Anti CD3 or PHA AIMV CD3/CD28 beads or PHA 5 to 2% FBS Medium HIV infected CD4+ cells from PBMC 2–3 107 NP Cellmax Quad NP NP NP 50 Keep glucose above 50% of the baseline value
 De Bartolo [114] - 2007 PHA DMEM NP 10% FBS Medium PBMC 8 × 107 24 PEEK-WC-HF NP NP 128 5 to 10 NP
 Curcio [128] - 2012 PHA DMEM PHA 10% FBS Medium PBMC 8 × 107 25 Parallel-HFMBR NP NP 128 2–10 Adjust concentrations to number of cells
 Curcio [128] - 2012 PHA DMEM PHA 10% FBS Medium PBMC 8 × 107 35 Crossed-HFMBR NP NP NP 2–10 Adjust concentrations to number of cells
 Nankervis [111] - 2018 IL2, Anti CD3/CD8 beads + IL7 NP IL2; IL7 NP Cells PBMC NP 100 Quantum 1st generation protocol 11,520 17 NP EC: 100
IC: 1
NP
 Nankervis [111] - 2018 IL2, Anti CD3/CD8 beads NP IL2 NP Cells PBMC NP 100 Quantum 2nd generation protocol 11,520 17 NP Max. 300 NP
 Coeshott [112] - 2019 IL2, Anti CD3/CD8 beads PRIME-XV NP NP Cells PBMC 3.0–8.5 × 107 124 Quantum 11,520 17 21,000 Max. 300 (IC) Remove lactate
TIL
 Knazek [78] - 1990 IL2, Autol. LAK supern. and serum AIMV IL2 OR LAK supernatant. + HS Glucose and glutamine Medium Melanoma NP 50 Cellmax 100 8000   11,000 40–300n Control glucose at
1–1.5 g/L
 Hillman [115] - 1994 IL2, TNFa AIMV IL2 10% AB RPMI Kidney tumors 5–30 × 108 30 IMMUNO*STAR® 1000 Cell Expander NP 10 3000 EC: 2
IC: 200
Control glucose
 Freedman [119] - 1994 IL2 AIMV IL2 NP Medium Ascites/pleural effusions/solid tumors 109 NP Cellmax 100 8000 4 23,000 60–300 Control glucose
 Lewko [129] - 1994 IL2, Autol. LAK supern. and serum AIMV IL2 NP Medium Tumor 1–2 × 109 NP Cellmax 100 NP 4 23,000 NP Control glucose between 1.0–1.5 g/L
 Lewko [117] - 2000 IL2, Autol. LAK supern. and serum AIMV IL2 NP Medium Tumor 1–2 × 109 NP Cellmax 100 NP NP 23,000 NP Control glucose between 1.0–1.5 g/L
 Freedman [130] - 2000 IL2 AIMV IL2 NP Medium Tumor samples 1–2 × 109 NP Cellmax 100 NP NP NP NP NP
 Malone [118] - 2001 IL2, OKT3 AIMV IL2 Glutamine Medium Tumor samples 4–6 × 108 100 Celco - not specified NP 30–150 2200 NP Keep lactate below 1000 units/mL
PBL
 Pan [120] - 1999 IL2, OKT3 AIMV IL2 5% FBS, glutamine Medium PBL 5–9.3 × 107 NP Cellmax Quad pump station NP NP NP NP Controlling lactate levels
 Shankar [121] - 1997 OKT3 AIMV IL2 5% FBS, glutamine Medium PBL 5 × 107 11.4 Cellmax Artificial Capillary NP NP NP NP Keep lactate below 0.5 mg/mL
 Stroncek [122] - 1999 OKT3 AIMV IL2 5% FBS, glutamine Medium PBL 108 11 Cellmax Artificial Capillary NP NP NP NP NP
  1. NP Not published